A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo

  • End date
    Dec 23, 2022
  • participants needed
  • sponsor
    Incyte Corporation
Updated on 22 September 2021


The purpose of this study is to evaluate the efficacy and safety of INCB054707 over a 24-week placebo-controlled double-blind treatment period, followed by a 28-week double-blind extension period in participants with nonsegmental vitiligo.

Condition NonSegmental Vitiligo
Treatment Placebo, INCB054707
Clinical Study IdentifierNCT04818346
SponsorIncyte Corporation
Last Modified on22 September 2021


Yes No Not Sure

Inclusion Criteria

Clinical diagnosis of nonsegmental vitiligo
History of prior vitiligo treatment with a total duration of at least 3 months
Agreement to discontinue all agents and procedures used to treat vitiligo from screening through the final safety follow-up visit
Willingness to avoid pregnancy or fathering children
Further inclusion criteria apply

Exclusion Criteria

Other forms of vitiligo (eg, segmental) or other skin depigmentation disorders
Uncontrolled thyroid function at screening as determined by the investigator
Women who are pregnant (or who are considering pregnancy) or lactating
Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator
Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis
Participants known to be infected with HIV, Hepatitis B, or Hepatitis C
Laboratory values outside of the protocol-defined ranges
Further exclusion criteria apply
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note